Key Takeaways
- Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
- The company said the trial of suzetrigine met its primary endpoint in reducing pain, but a placebo reference arm also showed a “similar within-group reduction from baseline in pain.”
- With Thursday’s losses, Vertex shares fell into negative territory for the year.
Vertex Pharmaceuticals (VRTX) shares sank Thursday morning after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
The company said the trial of suzetrigine “met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale (NPRS).”
However, the placebo reference arm “showed a similar within-group reduction from baseline in pain with a mean change in NPRS at Week 12 of -1.98,” Vertex said. It added that “the study was not designed nor powered for statistical comparison between suzetrigine and placebo.”
Vertex shares fell 14% shortly after the opening bell Thursday, bringing them into negative territory for the year.
:max_bytes(150000):strip_icc()/GettyImages-1763769061-1faa7bf1d32e425a96a3857c3a98ef93.jpg?ssl=1&description=Vertex+Pharmaceuticals+Stock+Dives+After+Mixed+Drug+Study+Results){kind=link}